Insulet reports positive clinical trial results for Omnipod Horizon
Building on the success of its tubeless insulin delivery tech, Insulet (NSDQ:PODD) this week touted positive results from the latest clinical trial of its Omnipod Horizon automated glucose control system.
The study, which was conducted in a supervised hotel setting, included patients who use multiple daily injections or traditional insulin pumps to manage their diabetes. Participants had unrestricted access to meals and moderate-intensity exercise, according to Insulet.
The company reported that study participants spent significantly less time in hypoglycemia, more time in the target range and experienced better overnight glycemic control when using the Omnipod Horizon system compared to their traditional therapy.
Additionally, the system was safe for more than five days of use in adults, adolescents and kids, Insulet reported.
“We recognize that everyone’s treatment needs are different, and the Omnipod Horizon System provides individualized diabetes management to address real-world challenges,” Dr. Jennifer Sherr of Yale University School of Medicine said in prepared remarks. “One of the important features is the ability for users to tailor the system for exercise and high fat meals to maintain good glycemic control.”
“In the era of personalized medicine, Insulet is committed to bringing our innovative technology to the global diabetes community and our clinical data give us confidence that the Omnipod Horizon System will be a significant advancement in diabetes management,” Dr. Trang Ly, Insulet’s SVP & medical director, added.
NEXT: Diabeloop touts 12-week, real-world study of closed-loop system